Publications by authors named "Bernard Fine"

Claim this Profile
W
Whole-body CD8 T cell visualization before and during cancer immunotherapy: a phase 1/2 trial.
Laura Kist de Ruijter, Pim P van de Donk, Jahlisa S Hooiveld-Noeken, Danique Giesen, Sjoerd G Elias, Bernard M Fine

Nat Med· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical pharmacology of vc-MMAE antibody-drug conjugates in cancer patients: learning from eight first-in-human Phase 1 studies.
Chunze Li, Cindy Zhang, Zao Li, Divya Samineni, Dan Lu, Bernard M Fine

MAbs· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of DSTP3086S, an Antibody-Drug Conjugate Targeting Six-Transmembrane Epithelial Antigen of Prostate 1, in Metastatic Castration-Resistant Prostate Cancer.
Daniel C Danila, Russell Z Szmulewitz, Ulka Vaishampayan, Celestia S Higano, Ari D Baron, Bernard M Fine

J Clin Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using Zr-DFO-MSTP2109A Anti-STEAP1 Antibody.
Jorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, Steven M Larson, Stephen E Fleming

J Nucl Med· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Time-to-Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine-Citrulline-Monomethylauristatin E Antibody-Drug Conjugates.
Matts Kågedal, Divya Samineni, William R Gillespie, Dan Lu, Bernard M Fine

CPT Pharmacometrics Syst Pharmacol· August 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single cell-produced and in vitro-assembled anti-FcRH5/CD3 T-cell dependent bispecific antibodies have similar in vitro and in vivo properties.
Ayse Meric Ovacik, Ji Li, Marie Lemper, Dimitry Danilenko, Nicola Stagg, Bernard Fine

MAbs· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and Biodistribution of a [Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.
Joseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, Volkan Beylergil, Sarah M Cheal, Bernard M Fine

Mol Pharm· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer.
Frederike Bensch, Elly L van der Veen, Marjolijn N Lub-de Hooge, Annelies Jorritsma-Smit, Ronald Boellaard, Bernard M Fine

Nat Med· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Matts Kågedal, Leonid Gibiansky, Jian Xu, Xin Wang, Divya Samineni, Bernard M Fine

J Pharmacokinet Pharmacodyn· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Peripheral neuropathy with microtubule inhibitor containing antibody drug conjugates: Challenges and perspectives in translatability from nonclinical toxicology studies to the clinic.
Nicola J Stagg, Ben-Quan Shen, Flavia Brunstein, Chunze Li, Amrita V Kamath, Bernard M Fine

Regul Toxicol Pharmacol· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
Laetitia E Lamberts, Catharina W Menke-van der Houven van Oordt, Eva J ter Weele, Frederike Bensch, Michiel M Smeenk, Bernard M Fine

Clin Cancer Res· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pertuzumab and erlotinib in patients with relapsed non-small cell lung cancer: a phase II study using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging.
Brett Hughes, Linda Mileshkin, Peter Townley, Barbara Gitlitz, Keith Eaton, Bernard M Fine

Oncologist· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib.
Elizabeth A Punnoose, Siminder Atwal, Weiqun Liu, Rajiv Raja, Bernard M Fine

Clin Cancer Res· April 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Linda Mileshkin, Rodney J Hicks, Brett G M Hughes, Paul L R Mitchell, Veena Charu, Bernard M Fine

Clin Cancer Res· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer.
David S Binns, Andrea Pirzkall, Wei Yu, Jason Callahan, Linda Mileshkin, Bernard M Fine

Eur J Nucl Med Mol Imaging· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular biomarker analyses using circulating tumor cells.
Elizabeth A Punnoose, Siminder K Atwal, Jill M Spoerke, Heidi Savage, Ajay Pandita, Bernard M Fine

PLoS One· September 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a microarray platform for FFPET profiling: application to the classification of human tumors.
Sven Duenwald, Mingjie Zhou, Yanqun Wang, Serguei Lejnine, Amit Kulkarni, Bernard Fine

J Transl Med· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diurnal variation of the human adipose transcriptome and the link to metabolic disease.
Andrey Loboda, Walter K Kraft, Bernard Fine, Jeffrey Joseph, Michael Nebozhyn

BMC Med Genomics· February 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients.
Hongyue Dai, Laura van't Veer, John Lamb, Yudong D He, Mao Mao, Bernard M Fine

Cancer Res· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Distinct gene expression profiles determine molecular treatment response in childhood acute lymphoblastic leukemia.
Gunnar Cario, Martin Stanulla, Bernard M Fine, Oliver Teuffel, Nils V Neuhoff

Blood· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A genome-wide view of the in vitro response to l-asparaginase in acute lymphoblastic leukemia.
Bernard M Fine, Gertjan J L Kaspers, Minh Ho, Anne H Loonen, Linda M Boxer

Cancer Res· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene expression patterns associated with recurrent chromosomal translocations in acute lymphoblastic leukemia.
Bernard M Fine, Martin Stanulla, Martin Schrappe, Minh Ho, Susanne Viehmann

Blood· February 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis